ClinicalTrials.gg
Not yet recruitingNCT07796191Updated Sep 1, 2026

Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects

A Phase 1 interventional study of VC005 and verapamil and VC005 and probenecid in Healthy Adult Participants, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study includes three groups of Drug-Drug Interaction( DDI ) studies:

  1. To evaluate the effect of verapamil on the pharmacokinetics of a single oral dose of VC005 in healthy subjects;
  2. To evaluate the effect of probenecid on the pharmacokinetics of a single oral dose of VC005 in healthy subjects;
  3. To evaluate the effect of VC005 on the pharmacokinetics of a single oral dose of metformin tablets in healthy subjects.
02

Conditions studied

  • Healthy Adult Participants
03

In context

Lead sponsor

Jiangsu vcare pharmaceutical technology co., LTD is the lead sponsor of 35 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give written before study, and fully understand the study content, process and possible adverse reactions;
  2. Able to complete the study in compliance with the protocol;
  3. Subject (including partner) is willing to voluntarily take effective measures from screening through 3 months after the last dose of study drug ;
  4. Male and female subjects between the ages of 18 and 45 years, inclusive;
  5. At least 50.0kg for male subjects, 45.0kg for female subjects, with a (BMI= Weight/Height2) between 19.0-26.0 kg/m2, inclusive;

Exclusion criteria

Exclusion Criteria:

  1. More than 5 cigarettes per day on average within 3 months prior to screening;
  2. Subjects with a history of allergy, including allergy to drugs, food, dust mites, etc., or known to drugs of the same class as the product, or known hypersensitivity to verapamil, probenecid, metformin, or any of the ;
  3. History of drug and/or alcohol abuse (alcoholism defined as: drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or or have used drugs within the past five years;
  4. Donation or loss of a significant volume of blood (> 400 mL) within 3 months prior to screening;
  5. History of difficulties in swallowing or any history of gastrointestinal, liver, kidney disease (whether cured or not) or surgery that affects drug absorption or excretion;
  6. Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to receiving study drug;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    VC005 and verapamil

    Drug: VC005 and verapamil

  • Experimental
    VC005 and probenecid

    Drug: VC005 and probenecid

  • Experimental
    VC005 and metformin

    Drug: VC005 and metformin

Interventions

  • DrugVC005 and verapamil

    Drug pages: VC005 · Verapamil

    A single dose of VC005 was administered in the period 1. and a single dose of VC005 and verapamil coadministration in the period 2.

  • DrugVC005 and probenecid

    Drug pages: VC005 · Probenecid

    A single dose of VC005 was administered in the period 1. and a single dose of VC005 and probenecid coadministration in the period 2.

  • DrugVC005 and metformin

    Drug pages: VC005 · Metformin

    A single dose of metformin was administered in the period 1. and a single dose of metformin and VC005 coadministration in the period 2

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day1-Day12

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC)

    Time frame: Day1-Day12

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Nov 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2026
First posted
Sep 1, 2026
StartEst.
Sep 20, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07796191
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Sep 20, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Sep 1, 2026

Study contacts

linlin Hu
principal investigator · Zhongda Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: VC005 · Verapamil · Probenecid · Metformin

Start the discussion